CinCor Pharma, Inc. clinical trials
Acquired by AstraZeneca, Feb 24, 2023 · source ↗
The registry lists 2 studies whose lead sponsor is CinCor Pharma, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 1, 2023.
- 2studies on the registry
- 0open to participants now
Before and after it joined AstraZeneca
- First submitted before CinCor Pharma, Inc. became part of AstraZeneca
- 2
- First submitted after CinCor Pharma, Inc. became part of AstraZeneca
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs CinCor Pharma, Inc.’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 2
All 2 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed2100%
Over the years
- 120
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- CinCor Pharma, Inc.2 studies
Something wrong with this grouping? Tell us on the AstraZeneca page.
Studies
Recruiting first, then most recently updated. Showing 2 of 2. All AstraZeneca studies →
- A Study of CIN-107 in Patients With Uncontrolled HypertensionCompletedNCT05137002Phase 2
Sponsor listed in the registry: CinCor Pharma, Inc. · First submitted before CinCor Pharma, Inc. became part of AstraZeneca
- A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)CompletedNCT04519658Phase 2
Sponsor listed in the registry: CinCor Pharma, Inc. · First submitted before CinCor Pharma, Inc. became part of AstraZeneca